Navigation Links
Study Hints That Statins Might Fight Breast Cancer
Date:1/19/2012

By Denise Mann
HealthDay Reporter

THURSDAY, Jan. 19 (HealthDay News) -- Amid hints that statins -- cholesterol-lowering drugs -- might also play a role in preventing or treating certain types of cancer, new research sheds some light on how these drugs may help stop breast cancer in its tracks among certain women.

The p53 tumor suppressor gene stops the uncontrolled growth of cancer cells, but some women with breast cancer have mutant forms of this gene. In the new study, when the mutant p53 cells were treated in the laboratory with statins, the cells stopped their erratic growth, and even died in some cases.

It seems that the mutated p53 genes may activate the same pathway that the statins inhibit -- the mevalonate pathway, the study suggests. The mevalonate pathway is important in the body's production of cholesterol.

In the study, the effects of the statin drugs were erased when the mevalonate pathway was reactivated, supporting the potential mechanism. The new research is published in the Jan. 20 issue of the journal Cell.

Study author Dr. Carol Prives, chair of the department of biological sciences at Columbia University in New York City, is cautious in her enthusiasm about the results and their implications.

"The study is adding the possibility that there may be classes of breast cancer patients who will respond better to statins than others," she said, but noted that this research is far away from the bedside.

"By understanding better what sort of cells would respond to statins, one might have a better idea of whether or not to consider using them," she added. "The next step could be a trial of statins in women with breast cancer who have a mutated copy of the p53 gene."

Commenting on the study, cancer expert Marc Symons said, "This paper unravels a mechanism whereby p53, a frequently mutated cancer gene, promotes the aberrant behavior of cancer cells."

The mutated protein stimulates the mevalonate pathway, explained Symons, an investigator at the Center for Oncology and Cell Biology at the Feinstein Institute for Medical Research in Manhasset, N.Y.

"Statins, drugs that are widely used to lower cholesterol levels, block a key step in the mevalonate pathway," Symons said. "The new results may well give new momentum to the use of statins as anti-cancer agents."

Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, is also intrigued by the potential of the new findings.

"This paper addresses a possible new target for therapeutic agents based on a well-known tumor suppressor gene that is common in many cancers," Bernik said. "Identifying novel pathways that lead to tumor formation is the first step to developing new drugs that can specifically target some of the complex mechanisms that contribute to the development of cancer," she pointed out.

"This work and other projects like this raise the hope that we will one day be able to cure cancers on a molecular level," Bernik said.

More information

Learn more about how breast cancer is treated at the U.S. National Cancer Institute.

SOURCES: Carol Prives, Ph.D., DaCosta Professor of Biology and chair, department of biological sciences at Columbia University, New York City; Marc Symons, Ph.D., investigator, Center for Oncology and Cell Biology, Feinstein Institute of Medical Research, Manhasset, N.Y.; Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; Jan. 20, 2012, Cell


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. VCU study suggests antimicrobial scrubs may reduce bacteria
2. Narrowed Artery Condition Often Goes Undiagnosed: Study
3. Some Women Can Go Longer Between Bone Checks: Study
4. Study reveals mechanism of lung-cancer drug resistance
5. Study finds potential key to immune suppression in cancer
6. The Pill Can Help Ease Period Pain, Study Finds
7. University of Maryland study: Headphone-distracted pedestrians face death, serious injury
8. Study reveals origins of esophageal cancer
9. Researchers study how chemicals in drugs and around us impact stem cells
10. UH Case Medical Center publishes study on novel treatment for skin lymphoma
11. Retention study identifies key factors affecting 3 generations of nurses
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Hints That Statins Might Fight Breast Cancer
(Date:1/20/2017)... ... 2017 , ... Source Vitál Apothecary, a skin and body care company dedicated ... company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition ... in the nutritional, sports and health industries a chance to meet in private sessions ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation ... trial has been life-saving as she has been on the trial for more ... diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later ...
(Date:1/20/2017)... ... ... Magdalene: Grace is Greater than Sin”: a unique and memorable piece of literature ... Grace is Greater than Sin” is the creation of published author, Brenda Roberts, a ... had little knowledge of the female characters portrayed in the Holy Bible. , ...
(Date:1/20/2017)... ... ... examination of how God handles sin, including how to let go of lingering guilt and ... ten long years has been waiting to release this powerful insight about forgiveness that the ... the Lord for over twenty years, and he has been preaching and teaching the Word ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... ARMO BioSciences, Inc., a late-stage immuno-oncology company, ... lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) at the ... of Clinical Oncology (ASCO), taking place January 19-21, 2017 ... "AM0010 induces the expansion of novel T ... in the blood and tumors of our patients," said ...
(Date:1/20/2017)... , Jan 20, 2017 Research ... Testing Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, ... By End-use, And Segment Forecasts, 2013 - 2024" report to ... ... 198.5 billion by 2024 Introduction of innovative solutions on ...
(Date:1/20/2017)... DUBLIN , Jan 20, 2017 ... Pharmaceutical Stability Testing Market Trends, Opportunities, and Future" report to ... ... market sizing, emerging trends, and technologies, and provides a snapshot of ... year is 2015 and forecasts are provided from 2016 to 2020. ...
Breaking Medicine Technology: